Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Early Small (cT1N0) Triple Negative Breast Cancer
Interventions: DRUG: Durvalumab
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: AstraZeneca